色氨酸相关代谢产物在帕金森病中的研究进展
Research Progress of Tryptophan-Related Metabolites in Parkinson’s Disease
DOI: 10.12677/acm.2025.1541318, PDF,    科研立项经费支持
作者: 徐利丽, 邵 娴:绍兴市人民医院医学研究中心,浙江 绍兴;单 跃:绍兴市人民医院麻醉科,浙江 绍兴;何玲燕*:绍兴市人民医院中医科,浙江 绍兴
关键词: 色氨酸代谢产物帕金森病生物标志物Tryptophan Metabolites Parkinson’s Disease Biomarkers
摘要: 研究表明色氨酸代谢异常会影响神经功能,参与帕金森病(PD)的发生发展。本文综述了色氨酸三大代谢物途径,包括犬尿氨酸途径、血清素途径和吲哚代谢途径在PD进展中的作用。通过综合探讨色氨酸从饮食摄入,到肠道微生物分解,再到各种限速酶代谢合成,最终产生犬尿酸类、5-羟色胺和吲哚类物质,参与神经炎症、代谢、免疫反应和神经功能等病理生理过程,清晰地阐述不同代谢物调节PD发病的生物学作用及潜在机制。我们建议,对微生物组、色氨酸–犬尿氨酸途径代谢物和芳香烃受体的综合分析将有助于揭示PD发病的新机制,为PD的早期诊断和病情监测提供新思路。
Abstract: Studies have shown that abnormal tryptophan metabolism can affect neurological function and participate in the occurrence and development of Parkinson’s disease (PD). This article reviews the roles of three major metabolite pathways, including kynurenine pathway, serotonin pathway, and indole metabolic pathway, in the progression of PD. By comprehensively exploring the pathophysiological processes of neuroinflammation, metabolism, immune response and neurological function, the biological role and potential mechanism of different metabolites in regulating the pathogenesis of PD were clearly elaborated by comprehensively exploring the pathophysiological processes of tryptophan from dietary intake, intestinal microbial decomposition, and then to the metabolism and synthesis of various rate-limiting enzymes, and finally producing kynuculin, serotonin, and indole, which are involved in neuroinflammation, metabolism, immune response, and neurological function. We suggest that a comprehensive analysis of the microbiome, tryptophan-kynurenine pathway metabolites, and aryl hydrocarbon receptors will help to reveal new mechanisms of PD pathogenesis and provide new ideas for early diagnosis and disease monitoring of PD.
文章引用:徐利丽, 邵娴, 单跃, 何玲燕. 色氨酸相关代谢产物在帕金森病中的研究进展[J]. 临床医学进展, 2025, 15(4): 3455-3464. https://doi.org/10.12677/acm.2025.1541318

参考文献

[1] Bloem, B.R., Okun, M.S. and Klein, C. (2021) Parkinson’s Disease. The Lancet, 397, 2284-2303. [Google Scholar] [CrossRef] [PubMed]
[2] Nalls, M.A., Blauwendraat, C., Vallerga, C.L., Heilbron, K., Bandres-Ciga, S., Chang, D., et al. (2019) Identification of Novel Risk Loci, Causal Insights, and Heritable Risk for Parkinson’s Disease: A Meta-Analysis of Genome-Wide Association Studies. The Lancet Neurology, 18, 1091-1102. [Google Scholar] [CrossRef] [PubMed]
[3] Tanaka, M., Toldi, J. and Vécsei, L. (2020) Exploring the Etiological Links behind Neurodegenerative Diseases: Inflammatory Cytokines and Bioactive Kynurenines. International Journal of Molecular Sciences, 21, Article No. 2431. [Google Scholar] [CrossRef] [PubMed]
[4] Hestad, K., Alexander, J., Rootwelt, H. and Aaseth, J.O. (2022) The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases. Biomolecules, 12, Article No. 998. [Google Scholar] [CrossRef] [PubMed]
[5] Heilman, P.L., Wang, E.W., Lewis, M.M., Krzyzanowski, S., Capan, C.D., Burmeister, A.R., et al. (2020) Tryptophan Metabolites Are Associated with Symptoms and Nigral Pathology in Parkinson’s Disease. Movement Disorders, 35, 2028-2037. [Google Scholar] [CrossRef] [PubMed]
[6] Gao, K., Mu, C., Farzi, A. and Zhu, W. (2020) Tryptophan Metabolism: A Link between the Gut Microbiota and Brain. Advances in Nutrition, 11, 709-723. [Google Scholar] [CrossRef] [PubMed]
[7] Davidson, M., Rashidi, N., Nurgali, K. and Apostolopoulos, V. (2022) The Role of Tryptophan Metabolites in Neuropsychiatric Disorders. International Journal of Molecular Sciences, 23, Article No. 9968. [Google Scholar] [CrossRef] [PubMed]
[8] Pathak, S., Nadar, R., Kim, S., Liu, K., Govindarajulu, M., Cook, P., et al. (2024) The Influence of Kynurenine Metabolites on Neurodegenerative Pathologies. International Journal of Molecular Sciences, 25, Article No. 853. [Google Scholar] [CrossRef] [PubMed]
[9] Covarrubias, A.J., Perrone, R., Grozio, A. and Verdin, E. (2020) NAD+ Metabolism and Its Roles in Cellular Processes during Ageing. Nature Reviews Molecular Cell Biology, 22, 119-141. [Google Scholar] [CrossRef] [PubMed]
[10] Badawy, A.A. (2017) Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. International Journal of Tryptophan Research, 10. [Google Scholar] [CrossRef] [PubMed]
[11] Roth, W., Zadeh, K., Vekariya, R., Ge, Y. and Mohamadzadeh, M. (2021) Tryptophan Metabolism and Gut-Brain Homeostasis. International Journal of Molecular Sciences, 22, Article No. 2973. [Google Scholar] [CrossRef] [PubMed]
[12] Li, D., Yu, S., Long, Y., Shi, A., Deng, J., Ma, Y., et al. (2022) Tryptophan Metabolism: Mechanism-Oriented Therapy for Neurological and Psychiatric Disorders. Frontiers in Immunology, 13, Article ID: 985378. [Google Scholar] [CrossRef] [PubMed]
[13] Xue, C., Li, G., Zheng, Q., Gu, X., Shi, Q., Su, Y., et al. (2023) Tryptophan Metabolism in Health and Disease. Cell Metabolism, 35, 1304-1326. [Google Scholar] [CrossRef] [PubMed]
[14] Savitz, J. (2019) The Kynurenine Pathway: A Finger in Every Pie. Molecular Psychiatry, 25, 131-147. [Google Scholar] [CrossRef] [PubMed]
[15] Marszalek-Grabska, M., Walczak, K., Gawel, K., Wicha-Komsta, K., Wnorowska, S., Wnorowski, A., et al. (2021) Kynurenine Emerges from the Shadows—Current Knowledge on Its Fate and Function. Pharmacology & Therapeutics, 225, Article ID: 107845. [Google Scholar] [CrossRef] [PubMed]
[16] Ostapiuk, A. and Urbanska, E.M. (2021) Kynurenic Acid in Neurodegenerative Disorders—Unique Neuroprotection or Double-Edged Sword? CNS Neuroscience & Therapeutics, 28, 19-35. [Google Scholar] [CrossRef] [PubMed]
[17] Zhen, D., Liu, J., Zhang, X.D. and Song, Z. (2022) Kynurenic Acid Acts as a Signaling Molecule Regulating Energy Expenditure and Is Closely Associated with Metabolic Diseases. Frontiers in Endocrinology, 13, Article ID: 847611. [Google Scholar] [CrossRef] [PubMed]
[18] Krause, D., Suh, H., Tarassishin, L., Cui, Q.L., Durafourt, B.A., Choi, N., et al. (2011) The Tryptophan Metabolite 3-Hydroxyanthranilic Acid Plays Anti-Inflammatory and Neuroprotective Roles during Inflammation: Role of Hemeoxygenase-1. The American Journal of Pathology, 179, 1360-1372. [Google Scholar] [CrossRef] [PubMed]
[19] Xu, B., Zhang, P., Tang, X., Wang, S., Shen, J., Zheng, Y., et al. (2022) Metabolic Rewiring of Kynurenine Pathway during Hepatic Ischemia-Reperfusion Injury Exacerbates Liver Damage by Impairing NAD Homeostasis. Advanced Science (Weinh), 9, e2204697. [Google Scholar] [CrossRef] [PubMed]
[20] Guidetti, P., Bates, G.P., Graham, R.K., Hayden, M.R., Leavitt, B.R., MacDonald, M.E., et al. (2006) Elevated Brain 3-Hydroxykynurenine and Quinolinate Levels in Huntington Disease Mice. Neurobiology of Disease, 23, 190-197. [Google Scholar] [CrossRef] [PubMed]
[21] Sala, A., Campagnoli, M., Perani, E., Romano, A., Labò, S., Monzani, E., et al. (2004) Human Α-1-Microglobulin Is Covalently Bound to Kynurenine-Derived Chromophores. Journal of Biological Chemistry, 279, 51033-51041. [Google Scholar] [CrossRef] [PubMed]
[22] Tanaka, M. and Vécsei, L. (2021) Monitoring the Kynurenine System: Concentrations, Ratios or What Else? Advances in Clinical and Experimental Medicine, 30, 775-778. [Google Scholar] [CrossRef] [PubMed]
[23] Silva-Adaya, D., Pérez-De La Cruz, V., Villeda-Hernández, J., Carrillo-Mora, P., González-Herrera, I.G., García, E., et al. (2011) Protective Effect of L-Kynurenine and Probenecid on 6-Hydroxydopamine-Induced Striatal Toxicity in Rats: Implications of Modulating Kynurenate as a Protective Strategy. Neurotoxicology and Teratology, 33, 303-312. [Google Scholar] [CrossRef] [PubMed]
[24] Lee, S., Lim, H., Masliah, E. and Lee, H. (2011) Protein Aggregate Spreading in Neurodegenerative Diseases: Problems and Perspectives. Neuroscience Research, 70, 339-348. [Google Scholar] [CrossRef] [PubMed]
[25] Samadi, P., Grégoire, L., Rassoulpour, A., Guidetti, P., Izzo, E., Schwarcz, R., et al. (2005) Effect of Kynurenine 3‐hydroxylase Inhibition on the Dyskinetic and Antiparkinsonian Responses to Levodopa in Parkinsonian Monkeys. Movement Disorders, 20, 792-802. [Google Scholar] [CrossRef] [PubMed]
[26] Chang, K., Cheng, M., Tang, H., Huang, C., Wu, Y. and Chen, C. (2018) Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson’s Disease. Molecular Neurobiology, 55, 6319-6328. [Google Scholar] [CrossRef] [PubMed]
[27] Fathi, M., Taghizadeh, F., Mojtahedi, H., Zargar Balaye Jame, S. and Markazi Moghaddam, N. (2022) The Effects of Alzheimer’s and Parkinson’s Disease on 28-Day Mortality of Covid-19. Revue Neurologique, 178, 129-136. [Google Scholar] [CrossRef] [PubMed]
[28] Agus, A., Planchais, J. and Sokol, H. (2018) Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host & Microbe, 23, 716-724. [Google Scholar] [CrossRef] [PubMed]
[29] Ogawa, T., Matson, W.R., Beal, M.F., Myers, R.H., Bird, E.D., Milbury, P., et al. (1992) Kynurenine Pathway Abnormalities in Parkinson’s Disease. Neurology, 42, 1702-1702. [Google Scholar] [CrossRef] [PubMed]
[30] Meloni, M., Puligheddu, M., Carta, M., Cannas, A., Figorilli, M. and Defazio, G. (2020) Efficacy and Safety of 5‐hydroxytryptophan on Depression and Apathy in Parkinson’s Disease: A Preliminary Finding. European Journal of Neurology, 27, 779-786. [Google Scholar] [CrossRef] [PubMed]
[31] Imamdin, A. and van der Vorst, E.P.C. (2023) Exploring the Role of Serotonin as an Immune Modulatory Component in Cardiovascular Diseases. International Journal of Molecular Sciences, 24, Article No. 1549. [Google Scholar] [CrossRef] [PubMed]
[32] Skorobogatov, K., De Picker, L., Verkerk, R., Coppens, V., Leboyer, M., Müller, N., et al. (2021) Brain versus Blood: A Systematic Review on the Concordance between Peripheral and Central Kynurenine Pathway Measures in Psychiatric Disorders. Frontiers in Immunology, 12, Article ID: 716980. [Google Scholar] [CrossRef] [PubMed]
[33] Lovinger, D.M. (2008) Communication Networks in the Brain: Neurons, Receptors, Neurotransmitters, and Alcohol. Alcohol Research & Health, 31, 196-214.
[34] Fanciulli, G., Ruggeri, R.M., Grossrubatscher, E., Calzo, F.L., Wood, T.D., Faggiano, A., et al. (2020) Serotonin Pathway in Carcinoid Syndrome: Clinical, Diagnostic, Prognostic and Therapeutic Implications. Reviews in Endocrine and Metabolic Disorders, 21, 599-612. [Google Scholar] [CrossRef] [PubMed]
[35] Zajdel, P., Matłoka, M., Konieczny, J., Kos, T., Lammers, J.C., Cavalco, N.G., et al. (2025) Simultaneous 5-HT(1B)R Agonist/5-HT(6)R Antagonist Action as a Potential Treatment of Parkinson’s Disease and Its Comorbidities. The Journal of Pharmacology and Experimental Therapeutics, 392, Article ID: 100055. [Google Scholar] [CrossRef] [PubMed]
[36] Marano, M., Pilotto, A., Padovani, A., Gupta, D., Vivacqua, G., Magliozzi, A., et al. (2024) The Chronic Use of Serotonin Norepinephrine Reuptake Inhibitors Facilitates Dyskinesia Priming in Early Parkinson’s Disease. Journal of Neurology, 271, 3711-3720. [Google Scholar] [CrossRef] [PubMed]
[37] Jiang, L., Wu, Y., Mo, Y., Gou, L., Chen, M., Wang, Y., et al. (2023) The Effects of Paroxetine Therapy on Depressive Symptom and Motor Function in the Treatment of Depression with Parkinson’s Disease: A Meta-Analysis. Medicine, 102, e34687. [Google Scholar] [CrossRef] [PubMed]
[38] Quan, M., Gao, J., Xu, S., Guo, D., Jia, J. and Wang, W. (2023) Comparison of Tandospirone and Escitalopram as a Symptomatic Treatment in Multiple System Atrophy-Cerebellar Ataxia: An Open-Label, Non-Controlled, 4 Weeks Observational Study. Journal of Psychiatric Research, 168, 133-139. [Google Scholar] [CrossRef] [PubMed]
[39] Fakhoury, M. (2015) Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders. Molecular Neurobiology, 53, 2778-2786. [Google Scholar] [CrossRef] [PubMed]
[40] Sanidad, K.Z., Rager, S.L., Carrow, H.C., Ananthanarayanan, A., Callaghan, R., Hart, L.R., et al. (2024) Gut Bacteria-Derived Serotonin Promotes Immune Tolerance in Early Life. Science Immunology, 9, eadj4775. [Google Scholar] [CrossRef] [PubMed]
[41] Tronci, E., Lisci, C., Stancampiano, R., Fidalgo, C., Collu, M., Devoto, P., et al. (2013) 5-Hydroxy-Tryptophan for the Treatment of L-DOPA-Induced Dyskinesia in the Rat Parkinson’s Disease Model. Neurobiology of Disease, 60, 108-114. [Google Scholar] [CrossRef] [PubMed]
[42] Videnovic, A., Noble, C., Reid, K.J., Peng, J., Turek, F.W., Marconi, A., et al. (2014) Circadian Melatonin Rhythm and Excessive Daytime Sleepiness in Parkinson Disease. JAMA Neurology, 71, 463-469. [Google Scholar] [CrossRef] [PubMed]
[43] Zheng, K., Gao, B., Wang, H., He, J., Chen, H., Hu, Z., et al. (2024) Melatonin Ameliorates Depressive‐Like Behaviors in Ovariectomized Mice by Improving Tryptophan Metabolism via Inhibition of Gut Microbe Alistipes inops. Advanced Science, 11, e2309473. [Google Scholar] [CrossRef] [PubMed]
[44] Palagini, L., Manni, R., Aguglia, E., Amore, M., Brugnoli, R., Bioulac, S., et al. (2021) International Expert Opinions and Recommendations on the Use of Melatonin in the Treatment of Insomnia and Circadian Sleep Disturbances in Adult Neuropsychiatric Disorders. Frontiers in Psychiatry, 12, Article ID: 688890. [Google Scholar] [CrossRef] [PubMed]
[45] Ma, H., Yan, J., Sun, W., Jiang, M. and Zhang, Y. (2022) Melatonin Treatment for Sleep Disorders in Parkinson’s Disease: A Meta-Analysis and Systematic Review. Frontiers in Aging Neuroscience, 14, Article ID: 784314. [Google Scholar] [CrossRef] [PubMed]
[46] Wei, G.Z., Martin, K.A., Xing, P.Y., Agrawal, R., Whiley, L., Wood, T.K., et al. (2021) Tryptophan-Metabolizing Gut Microbes Regulate Adult Neurogenesis via the Aryl Hydrocarbon Receptor. Proceedings of the National Academy of Sciences, 118, e2021091118. [Google Scholar] [CrossRef] [PubMed]
[47] Clarke, G., Grenham, S., Scully, P., Fitzgerald, P., Moloney, R.D., Shanahan, F., et al. (2012) The Microbiome-Gut-Brain Axis during Early Life Regulates the Hippocampal Serotonergic System in a Sex-Dependent Manner. Molecular Psychiatry, 18, 666-673. [Google Scholar] [CrossRef] [PubMed]
[48] Zhou, Y., Zhao, W., Quan, W., Qiao, C., Cui, C., Hong, H., et al. (2021) Dynamic Changes of Activated AHR in Microglia and Astrocytes in the Substantia Nigra-Striatum System in an Mptp-Induced Parkinson’s Disease Mouse Model. Brain Research Bulletin, 176, 174-183. [Google Scholar] [CrossRef] [PubMed]
[49] Dodd, D., Spitzer, M.H., Van Treuren, W., Merrill, B.D., Hryckowian, A.J., Higginbottom, S.K., et al. (2017) A Gut Bacterial Pathway Metabolizes Aromatic Amino Acids into Nine Circulating Metabolites. Nature, 551, 648-652. [Google Scholar] [CrossRef] [PubMed]
[50] Russell, W.R., Duncan, S.H., Scobbie, L., Duncan, G., Cantlay, L., Calder, A.G., et al. (2013) Major Phenylpropanoid‐derived Metabolites in the Human Gut Can Arise from Microbial Fermentation of Protein. Molecular Nutrition & Food Research, 57, 523-535. [Google Scholar] [CrossRef] [PubMed]
[51] Zhou, Y., Chen, Y., He, H., Peng, M., Zeng, M. and Sun, H. (2023) The Role of the Indoles in Microbiota-Gut-Brain Axis and Potential Therapeutic Targets: A Focus on Human Neurological and Neuropsychiatric Diseases. Neuropharmacology, 239, Article ID: 109690. [Google Scholar] [CrossRef] [PubMed]
[52] Cheng, L., Wu, H., Cai, X., Zhang, Y., Yu, S., Hou, Y., et al. (2024) A Gpr35-Tuned Gut Microbe-Brain Metabolic Axis Regulates Depressive-Like Behavior. Cell Host & Microbe, 32, 227-243.e6. [Google Scholar] [CrossRef] [PubMed]
[53] Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., et al. (2014) The Gut Microbiota Influences Blood-Brain Barrier Permeability in Mice. Science Translational Medicine, 6, 263ra158. [Google Scholar] [CrossRef] [PubMed]
[54] Sampson, T.R., Debelius, J.W., Thron, T., Janssen, S., Shastri, G.G., Ilhan, Z.E., et al. (2016) Gut Microbiota Regulate Motor Deficits and Neuroinflammation in a Model of Parkinson’s Disease. Cell, 167, 1469-1480.e12. [Google Scholar] [CrossRef] [PubMed]
[55] Chen, S., Chen, C., Liao, H., Wu, Y., Liou, J., Wu, M., et al. (2022) Alteration of Gut Microbial Metabolites in the Systemic Circulation of Patients with Parkinson’s Disease. Journal of Parkinsons Disease, 12, 1219-1230. [Google Scholar] [CrossRef] [PubMed]
[56] Chung, S.H., Yoo, D., Ahn, T., Lee, W. and Hong, J. (2023) Profiling Analysis of Tryptophan Metabolites in the Urine of Patients with Parkinson’s Disease Using LC-MS/MS. Pharmaceuticals, 16, Article No. 1495. [Google Scholar] [CrossRef] [PubMed]
[57] Rothhammer, V., Mascanfroni, I.D., Bunse, L., Takenaka, M.C., Kenison, J.E., Mayo, L., et al. (2016) Type I Interferons and Microbial Metabolites of Tryptophan Modulate Astrocyte Activity and Central Nervous System Inflammation via the Aryl Hydrocarbon Receptor. Nature Medicine, 22, 586-597. [Google Scholar] [CrossRef] [PubMed]
[58] De Miranda, B.R., Miller, J.A., Hansen, R.J., Lunghofer, P.J., Safe, S., Gustafson, D.L., et al. (2013) Neuroprotective Efficacy and Pharmacokinetic Behavior of Novel Anti-Inflammatory Para-Phenyl Substituted Diindolylmethanes in a Mouse Model of Parkinson’s Disease. The Journal of Pharmacology and Experimental Therapeutics, 345, 125-138. [Google Scholar] [CrossRef] [PubMed]
[59] Scheperjans, F., Levo, R., Bosch, B., Lääperi, M., Pereira, P.A.B., Smolander, O., et al. (2024) Fecal Microbiota Transplantation for Treatment of Parkinson Disease: A Randomized Clinical Trial. JAMA Neurology, 81, 925-938. [Google Scholar] [CrossRef] [PubMed]
[60] Boros, F.A. and Vécsei, L. (2021) Tryptophan 2,3-Dioxygenase, a Novel Therapeutic Target for Parkinson’s Disease. Expert Opinion on Therapeutic Targets, 25, 877-888. [Google Scholar] [CrossRef] [PubMed]
[61] Iwaniak, P., Owe-Larsson, M. and Urbańska, E.M. (2024) Microbiota, Tryptophan and Aryl Hydrocarbon Receptors as the Target Triad in Parkinson’s Disease—A Narrative Review. International Journal of Molecular Sciences, 25, Article No. 2915. [Google Scholar] [CrossRef] [PubMed]
[62] Bai, J., Zheng, Y. and Yu, Y. (2020) Urinary Kynurenine as a Biomarker for Parkinson’s Disease. Neurological Sciences, 42, 697-703. [Google Scholar] [CrossRef] [PubMed]
[63] Tong, Q., Zhang, L., Yuan, Y., Jiang, S., Zhang, R., Xu, Q., et al. (2015) Reduced Plasma Serotonin and 5-Hydroxyindoleacetic Acid Levels in Parkinson’s Disease Are Associated with Nonmotor Symptoms. Parkinsonism & Related Disorders, 21, 882-887. [Google Scholar] [CrossRef] [PubMed]
[64] Fathi, M., Vakili, K., Yaghoobpoor, S., Tavasol, A., Jazi, K., Hajibeygi, R., et al. (2022) Dynamic Changes in Metabolites of the Kynurenine Pathway in Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 13, Article ID: 997240. [Google Scholar] [CrossRef] [PubMed]
[65] Fan, Y., Yang, W., Wu, W., Wang, X., Lin, Y., Wu, L., et al. (2024) Serum Neurotransmitter Analysis of Motor and Non-Motor Symptoms in Parkinson’s Patients. Frontiers in Aging Neuroscience, 16, Article ID: 1423120. [Google Scholar] [CrossRef] [PubMed]
[66] Shao, Y., Li, T., Liu, Z., Wang, X., Xu, X., Li, S., et al. (2021) Comprehensive Metabolic Profiling of Parkinson’s Disease by Liquid Chromatography-Mass Spectrometry. Molecular Neurodegeneration, 16, Article No. 4. [Google Scholar] [CrossRef] [PubMed]